

Challenges in epidemiological research of childhood cancer

Paolo Boffetta



International Agency for Research on Cancer
Lyon, France


Automated Childhood Cancer Information System (ACCIS)

- Collection, presentation, and interpretation of data for cancer incidence and survival in children (aged 0–14) and adolescents (aged 15–19) in 35 European countries
- Data from 80 population-based cancer registries covering about half the population aged 0–14 years
- It includes 160 000 cases of childhood and adolescent cancer diagnosed from 1970 to 2001 (1.3 billion person-years)
- Funded by DG-SANCO, IARC, Scotland MoH


ACCIS coverage




Incidence rate of childhood cancer (0-14) in selected European countries - 1990s




Percentage of groups of childhood cancer (0-14) in selected European countries - 1990s




Age- and sex-specific incidence rates of groups of childhood cancer in Europe - 1990s




Age-specific percentage of groups of childhood cancer in Europe - 1990s




Decade- and age-specific incidence rate of childhood cancer in Europe



Annual percentage change in the incidence of groups of childhood cancer in Europe – 1970-2000



Survival from childhood cancer by European region – 1970-2000



Cases at risk

1990s	29 957	12 173					4362	1343				
1980s	30 705	19 398	15 353	6 503			7954	3505	1993	924		
1970s	15 242	6 764	6 107	5 865	5 498	2 346	5 493	2 353	2 168	1 255	432	73

Issues in descriptive epidemiology of childhood cancer


- Completeness of diagnosis, registration and histologic characterization
- Geographic and temporal patterns in incidence may reflect differences and trends in exposure to environmental agents, diagnostic procedures, survival of high-risk individuals

Embryonal tumours


- Embryonal tumours are a group of specialised neoplasms characteristically seen in very young children
- The microscopic appearance of these neoplasms resembles the structures seen in developing tissues and organs in the embryo and fetus

Age-specific incidence of selected embryonal tumours


Neuroblastoma




Wilms tumour



Retinoblastoma



Hepatoblastoma



Age (years)

Age (years)

Etiological implication of these patterns

- The very young ages of diagnosis and the embryonal histology of these tumours implies a pre-natal origin
- Most if not all events leading to tumour development are likely to have occurred before birth
- Any post-natal exposures / influences of aetiological importance probably act soon after birth or in infancy

Etiological implication of these patterns


- Probably fewer steps involved in pathway from normal to malignant cell than adult cancers
- Consistent with undifferentiated nature of cells of origin and genetic factors may be important
- Effect is to reduce the number of steps in the carcinogenic pathway and/or speed up the process

Some features common to embryonal tumours

- Abnormal birthweight patterns
- Associations with congenital anomalies and syndromes
- Associations with germline mutations that also predispose to adult-onset cancers
- Heterogeneity within tumour types



Origin of neuroblastoma

- Malignant tumor of the cells of the neural crest
- Neural crest cells migrate to create the sympathetic nervous system, tissue of heart, jaw, head



Sites of Neuroblastoma

Figure IV.1 Percent distribution of neuroblastomas by primary site and age, all races, both sexes SEER, 1975-95



Genetic syndromes associated with NB

- Beckwith-Wiedemann syndrome
- Rubenstein-Taybi syndrome
- von Recklinghausen syndrome
- Hirschsprung's disease

- They explain a minority of cases
- Family history of disease occurs in <5% of cases

Maternal factors - 1


Younger Maternal Age

Study name

Statistics for each study

Odds ratio and 95% CI

	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value
N Carolina (<20 years)	1.645	0.932	2.903	1.715	0.086
Minnesota (21 years)	1.090	0.657	1.809	0.333	0.739
US/Canada (<20 years)	1.400	0.676	2.898	0.906	0.365
New York (<18 years)	0.690	0.408	1.166	-1.387	0.165
California (<20 years)	0.959	0.669	1.375	-0.227	0.820
Washington (<20 years)	0.720	0.433	1.198	-1.265	0.206
	0.982	0.801	1.204	-0.171	0.864



Maternal factors - 2


Older Maternal Age

Study name

Statistics for each study


Odds ratio and 95% CI

	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value
N Carolina (> 30 years)	0.762	0.324	1.794	-0.622	0.534
Minnesota (>35 years)	0.880	0.329	2.357	-0.254	0.799
New York (>35 years)	1.600	0.669	3.825	1.057	0.290
Germany (>35 years)	0.900	0.498	1.625	-0.349	0.727
US/Canada (>40 years)	3.500	0.714	17.146	1.545	0.122
New York (31-40 yrs)	1.270	1.005	1.604	2.003	0.045
Washington (>35 years)	1.030	0.659	1.609	0.130	0.897
California (>35 years)	0.816	0.574	1.159	-1.137	0.256
	1.086	0.924	1.276	1.006	0.314




Exposures in pregnancy - 1

Tobacco Use in Pregnancy




Exposures in pregnancy - 2

Alcohol Use in Pregnancy




Pregnancy-related factors - 1

Low Birthweight




Pregnancy-related factors - 2

High Birthweight



Exposures in childhood - 1

Breastfeeding



Exposures in childhood - 2


Child or Familial History of Allergic Diseases

Study name

Statistics for each study

Odds ratio and 95% CI

	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value
N Carolina - Allergies	0.220	0.060	0.813	-2.270	0.023
N Carolina - Asthma	1.660	0.222	12.432	0.493	0.622
Germany - Allergies	0.200	0.061	0.658	-2.648	0.008
US/Canada - Asthma	0.690	0.358	1.331	-1.107	0.268
US/Canada - Hay Fever	0.430	0.179	1.034	-1.886	0.059
US/Canada - Eczema	0.820	0.413	1.630	-0.566	0.571
US/Canada - Any allergic disease	0.680	0.436	1.060	-1.701	0.089
N Carolina - Maternal asthma	0.350	0.153	0.798	-2.496	0.013
N Carolina - Maternal allergies	0.660	0.267	1.632	-0.900	0.368
Germany - Maternal allergies	0.880	0.598	1.295	-0.648	0.517
	0.657	0.530	0.814	-3.841	0.000



Challenges in epidemiological research of childhood cancer

- Need to think about what the birthweights and anomalies are pointing to regarding critical stages of gestation at which risk factors may act
- Need to relate knowledge of biology and evolution of tumours to pre-natal and post-natal growth and development and descriptive epidemiology
- Need to think about what sorts of aetiological agents might produce these biological and epidemiological patterns
- Need to consider the role of genetic variability in susceptibility (of the child and the mother)

Timing of exposures

- Pre-conception
 - parental germ cells, de novo/inherited mutations and polymorphisms
 - parental exposures
- Pre-natal
 - tissue and organ development in embryo and fetus: what are the targets and critical periods?
 - growth factors and imprinting
 - transplacental factors, maternal exposures (including via father/partner etc)

Post-natal

- neonatal care, nutrition, infections etc.: what are the vulnerable organs/tissues and critical periods of growth and development?

Conclusions

- Incidence rates of childhood cancer have been increasing in the last decades in most countries
- It is unclear whether this reflects a real phenomenon or an artifact due to better diagnosis and reporting
- Current knowledge on etiological factors of childhood cancer remains limited
- Future studies should integrate epidemiology, clinical research, genetics and molecular biology


The ISET study

- Case-control study of non-CNS solid tumours in childhood
- Large-scale collaboration
 - epidemiologists; clinicians (SIOP); geneticists
- Emphasis on gene-environment interactions
- NB, RMS as pilot projects

ISET participants


- **France**
 - INSERM: Florence Menegaux, Jacqueline Clavel
- **Italy**
 - Ospedale Pediatrico Bambino Gesù: Marina Cuttini
 - U. Turin: Corrado Magnani, Franco Merletti
- **Germany**
 - U. Mainz: Maria Blettner
- **The Netherlands**
 - Radboud U. Nijmegen Medical Centre: Nel Roeleveld
- **UK**
 - University of Manchester: Jillian Birch
 - ICR: Kathy Pritchard-Jones
 - U. Leeds: Patricia McKinney
 - U. Oxford: Michael Murphy
- **Czech Republic**
 - Vladimir Bencko
- **Serbia and Slovenia**
 - Simona Ognjanovic
- **Switzerland**
 - U. Bern: Claudia Kuehni
- **USA**
 - U. Berkeley: Patria Buffler
- **Canada**
 - SLRI / U. Toronto : Rayjean Hung
- **Brazil**
 - A C Camargo Cancer Hospital: Beatriz de Camargo, Karina Braga Ribeiro
 - NIC, Rio de Janeiro: Maria S. Pombo de Oliveira
- **India**
 - Tata Memorial Centre : PA Kurkure
- **Japan**
 - National Research Institute for Child Health and Development : Tomohiro Saito
- **Australia**
 - Institute for Child Health Research: Liz Milne

Incidence rate of groups of childhood cancer (0-14) in selected European countries - 1990s




Exposures in pregnancy - 3

Recreational Drug Use in Pregnancy




Pregnancy-related factors - 3

Preterm Birth



Exposures in childhood - 1

Birth Order or Family Size



This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.